Plasma Exchange in ANCA-Associated Vasculitis With Kidney Involvement: Differential Outcomes by Kidney Function in a

Clara Escorcia-García1, Mauricio Restrepo-Escobar2, Lina Aguirre3

  • 1Department of Internal Medicine, Division of Nephrology, University of Antioquia, Medellín, Colombia.

PubMed

Insights

Plasma exchange (PLEX) did not reduce mortality or end-stage kidney disease (ESKD) in ANCA-associated vasculitis (AAV) overall. However, PLEX showed benefit for patients with severe kidney dysfunction (creatinine > 5.7 mg/dL).

Area of Science:

  • Nephrology
  • Rheumatology
  • Immunology

Background:

  • ANCA-associated vasculitis (AAV) commonly affects the kidneys, potentially leading to end-stage kidney disease (ESKD).
  • The efficacy of plasma exchange (PLEX) in managing kidney involvement in AAV is not well-established.

Purpose of the Study:

  • To evaluate the effectiveness of plasma exchange (PLEX) in patients with ANCA-associated vasculitis (AAV) and kidney dysfunction.
  • To determine if PLEX impacts the composite outcome of all-cause mortality or ESKD in AAV patients with impaired kidney function.

Main Methods:

  • Retrospective cohort study involving 163 patients with AAV and serum creatinine ≥ 1.5 mg/dL.
  • Comparison of outcomes between patients who received PLEX and those who did not.
  • Analysis of primary outcome (all-cause mortality or ESKD) and secondary outcomes, including in-hospital infections.

Main Results:

  • Overall, PLEX was not associated with a significant reduction in the composite outcome of mortality or ESKD (aHR 1.04).
  • In patients with baseline creatinine > 5.7 mg/dL, PLEX was linked to a lower risk of ESKD (aHR 0.38) and a borderline reduction in the composite outcome (HR 0.45, p=0.05).
  • Patients receiving PLEX experienced a significantly higher rate of in-hospital infections (aRR 4.66, p=0.001).

Conclusions:

  • Plasma exchange may not offer overall benefit for kidney outcomes in ANCA-associated vasculitis patients with moderate kidney dysfunction.
  • PLEX could be beneficial for selected AAV patients with severe kidney impairment, warranting further investigation.
  • Increased risk of in-hospital infections is a significant consideration when using PLEX in AAV patients.

Related Concept Videos

Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
370
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
1.3K
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
880
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
281
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
1.0K
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
380